-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on iBio, Inc. (IBIO): "we expect the stock to move in sympathy with readouts from WVE and ARWR"
-
-
-
-
-
-
-
Brookline Capital Markets Reiterates Buy Rating on iBio, Inc. (IBIO)
-
-
-
-
-
-
-
iBio, Inc. (IBIO) Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
-
-
-
-
-
430,619 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

